Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17
Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
Anidulafungin is a medicine being developed for treatment of adults with certain kinds of
fungal infections. This study is evaluating anidulafungin in children and adolescents who
have fever and a low white blood cell count (neutropenia).